Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Xencor ( (XNCR) ) is now available.
On July 31, 2025, Xencor announced the appointment of Raymond J. Deshaies, Ph.D., to its board of directors. Dr. Deshaies, a renowned biochemist and cell biologist with extensive experience in biotechnology and drug development, previously served as senior vice president of global research at Amgen Inc. His appointment is expected to bolster Xencor’s efforts in advancing its pipeline of XmAb drug candidates through clinical development, leveraging his deep understanding of biological mechanisms and track record of translating scientific insights into transformative medicines.
The most recent analyst rating on (XNCR) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Xencor stock, see the XNCR Stock Forecast page.
Spark’s Take on XNCR Stock
According to Spark, TipRanks’ AI Analyst, XNCR is a Neutral.
Xencor’s overall stock score is weighed down by significant financial performance issues, particularly in profitability and cash flow. Although technical analysis shows some short-term positive signals, the long-term trends remain bearish. Valuation concerns due to negative earnings are offset by positive corporate event news, suggesting future potential. However, the overall outlook remains cautious due to financial instability.
To see Spark’s full report on XNCR stock, click here.
More about Xencor
Xencor is a clinical-stage biopharmaceutical company focused on developing engineered antibodies for treating cancer and autoimmune diseases. The company utilizes its XmAb technology to create small structural changes in proteins, leading to new therapeutic mechanisms. With over 20 candidates in clinical development and multiple marketed medicines through partners, Xencor is advancing its pipeline of novel drug candidates.
Average Trading Volume: 846,657
Technical Sentiment Signal: Sell
Current Market Cap: $627.7M
Learn more about XNCR stock on TipRanks’ Stock Analysis page.